THERAPEUTICS
Oral vitamin K did not reduce bleeding in patients with excessive anticoagulation after receiving warfarin
| The first 150 words of the full text of this article appear below. |
STUDY DESIGN
randomised, placebo-controlled trial. ClinicalTrials.gov NCT00143715 [ClinicalTrials.gov] .
concealed.*
blinded (patients, clinicians, research coordinators, and outcome adjudicators).*
STUDY QUESTION
14 anticoagulant centres in the USA, Canada, and Italy.
724 outpatients
18 years of age (mean age 69 y, 53% men) who attended clinic for routine international normalised ratio (INR) assessment, were receiving warfarin with a target INR of 2.0–3.5, were not bleeding, and had an INR between 4.5 and 10.0 in the past 24 hours. Exclusion criteria included life expectancy <10 days, indication for acute normalisation of INR, scheduled discontinuation of warfarin, known bleeding disorder, recent major bleeding, inability to take oral medication or undergo follow-up, contraindication to vitamin K, severe liver disease, thrombolytic therapy within 48 hours, and platelet count <50 x 109 cells/l.
single-dose oral vitamin K, 1.25 mg (n = 355), or placebo (n = 369).
any bleeding events at 90 days. Secondary outcomes included major bleeding (fatal bleeding, bleeding requiring
University of Utah, Salt Lake City, Utah, USA
Register for free content
The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.
Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.
